Parkinson's Clinical Research
ADepT PD Study
Trial of two drugs, Escitalopram and Nortripyline, for Depression in Parkinson's
ADepT-PD.pptxChief Investigator: Professor Anette Schrag, UCL, London
Recruiting Sites: Royal Free Hospital (Lead Site); University College Hospital; Campus for Ageing and Vitality; Queen Elizabeth Hospital; North Tyneside General Hospital; Luton & Dunstable Hospital; Charing Cross Hospital; Livewell Southwest; St Peter's Hospital; Royal Cornwall Hospital.
Timeframe: scheduled study end date is the 30th April 2023
UK Recruitment Target: 408
Link to further information: ADepT-PD - University College London
Further Information
Study Goal:
Depression is experienced by 40% of people with Parkinson's. Even though depression in people with Parkinson's is common, the best antidepressant drug for people with Parkinson's has not been confirmed yet. This trial tests two different antidepressant drugs for their effect on depression in Parkinson's. The two drugs are called escitalopram and nortriptyline.
Anyone receiving or needing psychological care continues to receive this while participating in the study. There are three groups of participants: people taking escitalopram, people taking nortriptyline and people taking placebo (a "fake" pill that looks identical but contains no drug). Participants are randomly put into one of these three groups.
Study Status:
This study is now closed to recruitment. The follow up visits are still taking place. The results are expected later in 2023 so stay tuned!
If you or someone you know are struggling please reach out & talk to someone or visit the Every Mind Matters website
